two new injectable diabetes drugs, Byetta (exenatide) and Symlin (pramlintide)

June 2005

There's a lot of interest in two new injectable diabetes drugs, Byetta (exenatide) and Symlin (pramlintide).

These drugs are the first of their kind. They both mimic hormones that help regulate blood glucose.

Byetta is an incretin mimetic. It's the one that's based on a protein derived from Gila monster saliva.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote